EDSA
vs
S&P 500
EDSA
S&P 500
Over the past 12 months, EDSA has underperformed S&P 500, delivering a return of -64% compared to the S&P 500's +14% growth.
Stocks Performance
EDSA vs S&P 500
Performance Gap
EDSA vs S&P 500
Performance By Year
EDSA vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Edesa Biotech Inc
Glance View
Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The company is headquartered in Markham, Ontario and currently employs 16 full-time employees. The company went IPO on 2008-08-25. The firm is focused on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune related diseases with clear unmet medical needs. The company is organized under the laws of British Columbia, Canada. The Company’s two lead product candidates, EB05 and EB01, are in later stage clinical studies. EB05 is a monoclonal antibody therapy, which the Company is developing as a treatment for acute respiratory distress syndrome (ARDS) in COVID19 patients. ARDS is a life-threatening form of respiratory failure and the leading cause of death among COVID19 patients. ARDS can be also caused by bacterial pneumonia, sepsis, chest injury and other causes. The company is developing a secreted phospholipases A2 (sPLA2) inhibitor, designated as EB01, as a treatment for chronic allergic contact dermatitis, a common, potentially debilitating condition and occupational illness. EB01 employs a nonsteroidal mechanism of action.
